HC Wainwright Reaffirms Buy Rating for BioNTech (NASDAQ:BNTX)

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $107.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 24.20% from the stock’s current price.

Several other equities research analysts have also issued reports on the stock. UBS Group lowered their price target on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a report on Wednesday, March 27th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.00 price objective on shares of BioNTech in a report on Thursday, March 21st. The Goldman Sachs Group dropped their target price on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 28th. JPMorgan Chase & Co. decreased their price target on BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a research note on Friday, March 22nd. Finally, Oppenheimer assumed coverage on shares of BioNTech in a research report on Friday, January 5th. They set a “market perform” rating for the company. One analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $120.40.

BioNTech Stock Performance

BNTX stock traded down $0.19 during trading on Wednesday, reaching $86.15. 1,063,601 shares of the stock were exchanged, compared to its average volume of 668,485. BioNTech has a twelve month low of $85.21 and a twelve month high of $125.83. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $20.48 billion, a P/E ratio of 20.91 and a beta of 0.23. The stock has a 50 day simple moving average of $91.67 and a 200-day simple moving average of $97.64.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.64 by ($0.59). The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a return on equity of 4.60% and a net margin of 24.26%. As a group, sell-side analysts anticipate that BioNTech will post -1.67 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BNTX. Eagle Bay Advisors LLC acquired a new position in shares of BioNTech during the second quarter valued at $33,000. State of Wyoming bought a new stake in BioNTech during the 2nd quarter worth about $26,000. CWM LLC lifted its position in BioNTech by 657.6% during the 4th quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after purchasing an additional 217 shares during the period. GAMMA Investing LLC boosted its stake in shares of BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after purchasing an additional 150 shares during the last quarter. Finally, Frazier Financial Advisors LLC acquired a new stake in shares of BioNTech during the 4th quarter worth approximately $30,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.